Skip to main content
Erschienen in: Rheumatology International 12/2016

08.10.2016 | Observational Research

Outcome and prognostic factors in a French cohort of patients with myositis-associated interstitial lung disease

verfasst von: Julie Obert, Olivia Freynet, Hilario Nunes, Pierre-Yves Brillet, Makoto Miyara, Robin Dhote, Dominique Valeyre, Jean-Marc Naccache

Erschienen in: Rheumatology International | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Interstitial lung disease (ILD) is a common form of extramuscular involvement in patients with polymyositis/dermatomyositis and is associated with poor prognosis. This study was designed to describe the long-term outcome of myositis-associated ILD. This retrospective observational study was conducted in 48 consecutive patients. Two groups defined according to outcome were compared to determine prognostic factors: a “severe” group (vital capacity [VC] < 50 % or carbon monoxide transfer factor [TLCO] < 35 % or death or lung transplantation) and a “nonsevere” group (other patients). The study population comprised 31 women and 17 men with a median age of 49.5 ± 13.6 years. Mean PFT results at the onset of ILD were 56.9 ± 23.1 % pred. for VC and 42.1 ± 16.6 % pred. for TLCO. Median (range) follow-up was 65 (2–204) months. Three patients (6.4 %) died. At last follow-up, 19 patients were classified in the “severe” group and 27 patients were classified in the “nonsevere” group. Two patients lost to follow-up after less than 12 months were excluded from this analysis. Multivariate analysis identified two independent prognostic factors: VC at onset of ILD [OR 0.95 (95 % CI 0.90–0.99)] and myopathic changes on electromyography [OR 5.76 (95 % CI 1.10–30.3)]. Patients treated in our pulmonology department for myositis-associated ILD had severe initial PFT results but a low mortality rate. Independent prognostic factors at presentation were initial VC and myopathic changes on electromyography. This study highlights the need for studies focusing on the correlation between muscle and lung pathogenic mechanisms.
Literatur
3.
Zurück zum Zitat Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 84(4):231–249CrossRefPubMed Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 84(4):231–249CrossRefPubMed
5.
Zurück zum Zitat Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH et al (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70(6):360–374CrossRefPubMed Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH et al (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70(6):360–374CrossRefPubMed
6.
Zurück zum Zitat Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK et al (1990) Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 77(282):1019–1038CrossRefPubMed Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK et al (1990) Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 77(282):1019–1038CrossRefPubMed
7.
Zurück zum Zitat Dickey BF, Myers AR (1984) Pulmonary disease in polymyositis/dermatomyositis. Sem Arthritis Rheum 14(1):60–76CrossRef Dickey BF, Myers AR (1984) Pulmonary disease in polymyositis/dermatomyositis. Sem Arthritis Rheum 14(1):60–76CrossRef
8.
Zurück zum Zitat Hepper NG, Ferguson RH, Howard FM Jr (1964) Three types of pulmonary involvement in polymyositis. Med Clin N Am 48:1031–1042CrossRefPubMed Hepper NG, Ferguson RH, Howard FM Jr (1964) Three types of pulmonary involvement in polymyositis. Med Clin N Am 48:1031–1042CrossRefPubMed
11.
Zurück zum Zitat Arakawa H, Yamada H, Kurihara Y, Nakajima Y, Takeda A, Fukushima Y et al (2003) Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: serial high-resolution CT findings and functional correlation. Chest 123(4):1096–1103CrossRefPubMed Arakawa H, Yamada H, Kurihara Y, Nakajima Y, Takeda A, Fukushima Y et al (2003) Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: serial high-resolution CT findings and functional correlation. Chest 123(4):1096–1103CrossRefPubMed
12.
Zurück zum Zitat Cottin V, Thivolet-Bejui F, Reynaud-Gaubert M, Cadranel J, Delaval P, Ternamian PJ et al (2003) Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 22(2):245–250CrossRefPubMed Cottin V, Thivolet-Bejui F, Reynaud-Gaubert M, Cadranel J, Delaval P, Ternamian PJ et al (2003) Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. Eur Respir J 22(2):245–250CrossRefPubMed
13.
Zurück zum Zitat Mira-Avendano IC, Parambil JG, Yadav R, Arrossi V, Xu M, Chapman JT et al (2013) A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. Respir Med 107(6):890–896. doi:10.1016/j.rmed.2013.02.015 CrossRefPubMed Mira-Avendano IC, Parambil JG, Yadav R, Arrossi V, Xu M, Chapman JT et al (2013) A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. Respir Med 107(6):890–896. doi:10.​1016/​j.​rmed.​2013.​02.​015 CrossRefPubMed
15.
Zurück zum Zitat Shinohara T, Hidaka T, Matsuki Y, Ishizuka T, Takamizawa M, Kawakami M et al (1997) Rapidly progressive interstitial lung disease associated with dermatomyositis responding to intravenous cyclophosphamide pulse therapy. Intern Med 36(7):519–523CrossRefPubMed Shinohara T, Hidaka T, Matsuki Y, Ishizuka T, Takamizawa M, Kawakami M et al (1997) Rapidly progressive interstitial lung disease associated with dermatomyositis responding to intravenous cyclophosphamide pulse therapy. Intern Med 36(7):519–523CrossRefPubMed
16.
Zurück zum Zitat Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y et al (2012) Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology 51(9):1563–1570. doi:10.1093/rheumatology/kes102 CrossRefPubMed Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y et al (2012) Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology 51(9):1563–1570. doi:10.​1093/​rheumatology/​kes102 CrossRefPubMed
17.
Zurück zum Zitat Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF (2011) Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 63(11):3439–3447. doi:10.1002/art.30513 CrossRefPubMed Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF (2011) Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 63(11):3439–3447. doi:10.​1002/​art.​30513 CrossRefPubMed
18.
Zurück zum Zitat Johnson C, Pinal-Fernandez I, Parikh R, Paik J, Albayda J, Mammen AL, Christopher-Stine L, Danoff S (2016) Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease. Lung 194(5):733–737. doi:10.1007/s00408-016-9896 CrossRefPubMed Johnson C, Pinal-Fernandez I, Parikh R, Paik J, Albayda J, Mammen AL, Christopher-Stine L, Danoff S (2016) Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease. Lung 194(5):733–737. doi:10.​1007/​s00408-016-9896 CrossRefPubMed
19.
Zurück zum Zitat Tillie-Leblond I, Wislez M, Valeyre D, Crestani B, Rabbat A, Israel-Biet D et al (2008) Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 63(1):53–59. doi:10.1136/thx.2006.069237 CrossRefPubMed Tillie-Leblond I, Wislez M, Valeyre D, Crestani B, Rabbat A, Israel-Biet D et al (2008) Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 63(1):53–59. doi:10.​1136/​thx.​2006.​069237 CrossRefPubMed
20.
Zurück zum Zitat Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824. doi:10.1164/rccm.2009-040GL CrossRefPubMed Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK et al (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824. doi:10.​1164/​rccm.​2009-040GL CrossRefPubMed
21.
22.
Zurück zum Zitat Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG et al (2013) An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188(6):733–748. doi:10.1164/rccm.201308-1483ST CrossRefPubMed Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG et al (2013) An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188(6):733–748. doi:10.​1164/​rccm.​201308-1483ST CrossRefPubMed
23.
Zurück zum Zitat Kambouchner M, Levy P, Nicholson AG, Schubel K, Magois E, Feuillet S et al (2014) Prognostic relevance of histological variants in nonspecific interstitial pneumonia. Histopathology 65:549–560. doi:10.1111/his.12415 CrossRefPubMed Kambouchner M, Levy P, Nicholson AG, Schubel K, Magois E, Feuillet S et al (2014) Prognostic relevance of histological variants in nonspecific interstitial pneumonia. Histopathology 65:549–560. doi:10.​1111/​his.​12415 CrossRefPubMed
24.
Zurück zum Zitat Schnabel A, Reuter M, Biederer J, Richter C, Gross WL (2003) Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 32(5):273–284. doi:10.1053/sarh.2002.50012 CrossRefPubMed Schnabel A, Reuter M, Biederer J, Richter C, Gross WL (2003) Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 32(5):273–284. doi:10.​1053/​sarh.​2002.​50012 CrossRefPubMed
27.
Zurück zum Zitat Gordon PA, Winer JB, Hoogendijk JE, Choy EH (2012) Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 8:CD003643. doi:10.1002/14651858.CD003643.pub4 Gordon PA, Winer JB, Hoogendijk JE, Choy EH (2012) Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 8:CD003643. doi:10.​1002/​14651858.​CD003643.​pub4
Metadaten
Titel
Outcome and prognostic factors in a French cohort of patients with myositis-associated interstitial lung disease
verfasst von
Julie Obert
Olivia Freynet
Hilario Nunes
Pierre-Yves Brillet
Makoto Miyara
Robin Dhote
Dominique Valeyre
Jean-Marc Naccache
Publikationsdatum
08.10.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Rheumatology International / Ausgabe 12/2016
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-016-3571-7

Weitere Artikel der Ausgabe 12/2016

Rheumatology International 12/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.